Objectives: It is to evaluate the effect of black cohosh on genital atrophy and its adverse effect in postmenopausal women. Methods: A total of 100 postmenopausal women having moderate to severe degree of climacteric symptoms were randomly allocated to receive black cohosh combined proparation (n = 50) or placebo (n = 50) daily for 12 weeks. A total of seventy eight subjects completed the study. The effect of black cohosh on vaginal atrophy was evaluated by measuring Maturation value (MV). MV was determined from vaginal smear at 0 and 12 weeks of treatment. Safety assessment included vital signs, physical examinations, adverse events, and routine laboratory parameters. Assessments were carried out at the beginning, and after 4, 8, and 12 weeks of treatment. Results: The mean (± standard deviation) MV decreased 0.18 (0.48 ± 0.33 to 0.30 ± 0.24) in the black cohosh group and 0.13 (0.44 ± 0.31 to 0.31 ± 0.22) in the placebo group. There was no statistical difference between the groups. But adverse events were observed in 7 (14%) patients in the black cohosh group and 6 (12%) patients in the placebo group, without statistical significance. No significant effects were observed on blood pressure, heart rate, body temperature, physical findings, and laboratory values. Black cohosh was well tolerated. Conclusion: Black cohosh did not exert estrogenic effects with regards to vaginal atrophy. Further studies on the long-term safety and the appropriate doses of cohosh are needed.
studies reported that the risk of breast cancer, cardiovascular diseases, thromboembolism, and dementia were increased by hormone replacement. As a result, a large number of menopausal women have discontinued taking hormones, and have turned to herbs, phytoestrogens, and dietary supplements instead because they worry about their reactions to hormones. These alternatives have been advertized as natural plant hormones that function like estrogen in selected tissues. Thus, they have been recognized as safer substitutes for hormones in terms of complications such as breast cancer.
Black cohosh has been most commonly used as a hormone substitute in western countries, and has been studied widely for treatment of menopausal symptoms. Black cohosh, a plant of the family of ranunculuses, is native to North America, and its root and rhizome have been used for medical treatments of conditions such as gynecological diseases over the past several hundred years. Black cohosh, which was first used by Native Americans, has been used as phytotherapy for the treatment of menopausal symptoms for 50 years in Europe. The German Commission E, which is a committee on herbal medicines in Germany, approved cohosh as a medicine for menopausal symptoms as well as premenstrual syndrome and menstrual pain. Recently, an effect of cohosh on menopausal symptoms such as febrile flushing has been proven in doubleblind, placebocontrolled studies. 4~13 Thus, cohosh has been used as a substitute for hormone replacement therapy. Although cohosh has been widely used to reduce menopausal symptoms for a long time, the effect of atrophy on the urogenital system has not yet been clarified, and controversy over the mechanism of action and characteristics of its estrogen remain. Recently, 4 cases of acute hepatic failure were reported in women who took varieties of cohosh; therefore, a concern over hepatotoxicity was raised. Cohosh's hepatotoxicity, which has been previously reported, was reviewed at the National 
Materials and Methods
The subjects were 100 menopausal women who had visited 
Results
Among the 100 patients who were randomly assigned to a cohosh or placebo group, excepting 22 patients who discontinued this trial, the number of PreProtocol (PP) patients who completed the clinical trial for 12 weeks was 78: 40 patients taking the cohosh complex medication, and 38 patients taking the placebo.
General characteristics
There were no significant differences in age, weight, height, blood pressure, or pulse between the two groups (Table 1 ). There were no significant differences in the combined drugs or medical history. In the placebo group, the most frequent adverse reaction was a gastrointestinal disorder, with 3 patients (7.8%), and next was reproductive system and breast disorders, with 2 patients (13.2%).
None of the 15 patients who dropped out early did so due to adverse reactions. The number of patients who had adverse reactions related to the prescribed medication was 7 (14%), in the cohoshcomplex medication group, which was somewhat higher than the placebo group, in which 6 (12%) had adverse reactions. The types of adverse reactions in the cohoshcomplex medication and the placebo groups were equal. It is thought that the causes of adverse reactions were not related to the cohoshcomplex medication.
Laboratory tests
There were no significant statistical differences between the cohoshcomplex medication and placebo groups' changes of the average and the normal range in all of the laboratory tests.
Vital signs / Physical examination
There were no differences in systolic blood pressure, diastolic blood pressure, pulse, or temperature between the two groups. There was no significant statistical difference between the two groups' physical examinations.
Discussion
Black cohosh (botanical name: Cimicifuga racemosa), which is native to North America, is a perennial plant. Its root and rhizome have been used for medical treatments such as gynecological diseases over the past few hundred years. Black cohosh, which was first used by the American Indians, has been used as phytotherapy for the treatment of 15 The use of a cohosh with modified lifestyle was recommended by North American Menopause Society to treat mild menopausal symptoms. 16 The use of cohosh is encouraged for treating menopausal symptoms including sleep disorders, menopausal depression, and febrile flushing lasting at least 6 months. 17 Cohosh consists of actein, cimicifugoside, and triterpene glycoside. In addition, it contains fukiictks, piscidic acid, salicylic acid, alkaloids, flavonoids, and tannins. 18, 19 However, recently, it has been thought that cohosh does not contain formononetin, which is commonly known as phytoestrogen.
Remifemin used, and various doses were prescribed in these studies.
In addition, the mechanism of action, characteristics of estrogen, and the effect of cohosh on urogenital atrophy related to safety have not been clarified.
Cohosh has been used as a safe substitute for febrile flushing and other menopausal symptoms over short periods; however, it has not been prescribed for long periods of time. Therefore, the safety of usage for more than 6 months is unknown. Generally, unlike prescription medications, natural herbal supplements are not controlled.
Thus, the quality of products, the safety, and the purity vary. In addition, safety should be considered because herbal supplements can produce interactions with prescribed medications.
In this study, observing changes in vaginal maturation values after prescribing the cohosh and St. John's wort for 12 weeks in natural menopausal women who had menopausal symptoms above the moderate level, it was shown that cohosh did not perform an estrogenlike function on the vagina because there was no significant difference between the cohosh and St, John's wortcomplex medication and placebo groups. There was no significant difference in adverse reaction rates between the cohosh complex medication and placebo groups, and there were no severe adverse reactions which could results in discontinuity of the study. The types of adverse reactions in the two groups were equal, and the cause of adverse reactions in the cohoshcomplex group was not related with cohosh complex medication. In addition, the safety of cohosh in the short term was demonstrated because the cohoshcomplex In conclusion, black cohosh did not exert estrogenic effects on the vaginal atrophy. Further studies on the longterm safety and appropriate doses of cohosh are needed.
